http://stroke.ahajournals.org/content/48/2/493?etoc=
This article requires a subscription to view the full text. If
you have a subscription you may use the login form below to view the
article. Access to this article can also be purchased.
Abstract
Background and Purpose—The
BEST-MSU study (Benefits of Stroke Treatment Delivered Using a Mobile
Stroke Unit) is a comparative effectiveness trial in patients randomized
to mobile stroke unit or standard management. A substudy tested
interrater agreement for tissue-type plasminogen activator eligibility
between a telemedicine vascular neurologist and onboard vascular
neurologist.
Methods—On
scene, both the telemedicine vascular neurologist and onboard vascular
neurologist independently evaluated the patient, documenting their
tissue-type plasminogen activator treatment decision, National
Institutes of Health Stroke Scale score, and computed tomographic
interpretation. Agreement was determined using Cohen κ statistic.
Telemedicine-related technical failures that impeded remote assessment
were recorded.
Results—Simultaneous
and independent telemedicine vascular neurologist and onboard vascular
neurologist assessment was attempted in 174 patients. In 4 patients
(2%), the telemedicine vascular neurologist could not make a decision
because of technical problems. The telemedicine vascular neurologist
agreed with the onboard vascular neurologist on 88% of evaluations
(κ=0.73).
Conclusions—Remote
telemedicine vascular neurologist assessment is reliable and accurate,
supporting either telemedicine vascular neurologist or onboard vascular
neurologist assessment on our mobile stroke unit.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT02190500.
No comments:
Post a Comment